Dr. Cohen on the DREAMM-2 Trial in Multiple Myeloma

Video

In Partnership With:

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

Adam D. Cohen, MD, assistant professor of medicine, director, Myeloma Immunotherapy, University of Pennsylvania, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

Prior to the trial, the phase I DREAMM-1 study demonstrated an overall response rate (ORR) of 60% with the investigational antibody-drug conjugate (ADC) belantamab mafodotin (GSK2857916).

DREAMM-2 is a registration study that is evaluating the ADC in a heavily pretreated and refractory population, explains Cohen. To be eligible for enrollment, patients had to have been exposed to a proteasome inhibitor, an immunomodulatory drug, and a CD38-targeted antibody.

In the trial, patients will be randomized to receive 3.4 mg/kg or 2.5 mg/kg of intravenous belantamab mafodotin. According to topline findings reported in a press release, belantamab mafodotin resulted in a clinically meaningful ORR in patients with relapsed myeloma, meeting the primary endpoint of the trial.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute